INVA 18.58 (+0.7%)
US45781M1018BiotechnologyBiotechnology

Innoviva (INVA) Stock Highlights

18.58 | +0.7%
2025-01-21 04:29:13
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravances respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.

Statistics

Range Today
18.44 18.61
Volume Today 606.5K
Range 1 Year
14.33 21.28
Volume 1 Year 150.67M
Range 3 Year
10.64 21.28
Volume 3 Year 542.45M
Range 10 Year
6.36 21.28
Volume 10 Year 2.01B

Highlights

Market Capitalization 1.16B (small)
Floating Shares 50.42M
Current Price 18.58
Price To Earnings 22.86
Price To Revenue 4.04
Price To Book 1.74
Earnings Per Share 0.81
Payout Ratio 0%

Performance

Latest +0.7%
1 Month +0.87%
3 Months -8.11%
6 Months +8.97%
1 Year +14.27%
3 Years +11.46%
5 Years +26.48%
10 Years +57.32%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.